← Back to Search

Virus Therapy

RPTR-168 for Melanoma

Phase 1
Waitlist Available
Research Sponsored by Repertoire Immune Medicines
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through approximately 1 year
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective at treating HPV-16 related cancers.

Eligible Conditions
  • Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Cervical Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through approximately 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through approximately 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency of dose interruptions
Number of subjects with dose limiting toxicities (DLT)
Secondary outcome measures
Area under the serum concentration-time curve
Best overall response
Immunogenicity of RPTR-168 as monotherapy
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: RPTR-168Experimental Treatment1 Intervention
Escalating doses of RPTR-168 as a monotherapy in HPV-16 E6/E7 positive tumors and melanoma.

Find a Location

Who is running the clinical trial?

Repertoire Immune MedicinesLead Sponsor
2 Previous Clinical Trials
45 Total Patients Enrolled
1 Trials studying Melanoma
22 Patients Enrolled for Melanoma
Daniel Vlock, MDStudy DirectorRepertoire Immune Medicines
4 Previous Clinical Trials
70 Total Patients Enrolled
David Spriggs, MDStudy DirectorRepertoire Immune Medicines
2 Previous Clinical Trials
45 Total Patients Enrolled
1 Trials studying Melanoma
22 Patients Enrolled for Melanoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are enrollment opportunities available for this clinical trial?

"The study, which was initially posted on May 10th 2021 and edited lastly on August 30th 2022 is not currently accepting candidates. Nonetheless, clinicaltrials.gov hosts 1,391 other trials requiring participants at this time."

Answered by AI

Are there any US-based medical centers undertaking this research program?

"Individuals interested in this trial may attend one of four medical centres, including USC Norris Comprehensive Cancer Center in Los Angeles, University of Michigan Comprehensive Cancer Centre in Ann Arbor, and HonorHealth Research Institute located in Scottsdale."

Answered by AI

What principal goals has this clinical research been designed to achieve?

"This trial is scheduled to conclude after 28 days and will be assessed by the number of subjects with dose limiting toxicities (DLT). Secondary endpoints include area under the serum concentration-time curve, immunogenicity of RPTR-168 as monotherapy, and best overall response per modified RECIST v1.1 (solid tumor)."

Answered by AI

Are there any unfavorable consequences related to the use of RPTR-168?

"There is limited evidence demonstrating the safety and efficacy of RPTR-168, resulting in it receiving a score of 1."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma
2021. "RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04762225.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top